Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


Real-time Estimate Quote. Real-time Estimate CHI-X - 12/01 10:55:00 am
416.3 DKK   -0.81%
08:56aNOVO NORDISK A/S : - Company announcements, trading in own shares
04:31aNOVO NORDISK A/S : ESG presentation ()
03:41aNOVO NORDISK : Gets a Buy rating from JP Morgan
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020

10/30/2020 | 01:30am EST

30 October 2020 - Financial report for the period 1 January 2020 to 30 September 2020

  • Sales increased by 6% in Danish kroner and by 7% at CER to DKK 94.8 billion. Sales in International Operations increased by 9% in Danish kroner (12% at CER), and sales in North America Operations increased by 2% in Danish kroner (2% at CER). Sales growth was negatively impacted by COVID-19 as fewer patients initiated treatment, partially offset by COVID-19-related stocking in the first quarter.
  • Sales within Diabetes and Obesity care increased by 6% to DKK 80.3 billion (8% at CER), driven by GLP-1 sales increasing by 29% in Danish kroner (29% at CER) reflecting the uptake of Ozempic® and the Rybelsus® launch as well as Obesity care sales increasing by 3% in Danish kroner (6% at CER). Biopharm sales increased by 3% (4% at CER).
  • Sales in the third quarter increased by 2% measured in Danish kroner and by 7% at CER compared to the third quarter of 2019. Sales growth was driven by GLP-1 sales increasing by 25% in Danish Kroner (31% at CER). 
  • During the third quarter, Novo Nordisk successfully completed the phase 2b trial with ziltivekimab in cardiovascular disease. Further, Novo Nordisk requested priority review in the US of the filing of semaglutide 2.4 mg in obesity based on a priority review voucher.
  • On 8 October, the outlook for 2020 was raised with sales growth and operating profit growth now both expected to be 5-8% at CER.
PROFIT AND LOSS9M 20209M 2019Growth
as reported
at CER*
DKK million    
Net sales94,808 89,604 6%7%
Operating profit42,948 40,610 6%7%
Net profit32,820 30,234 9%N/A
Diluted earnings per share (in DKK)14.00 12.68 10%N/A

* CER: Constant exchange rates (average 2019). The growth at CER was announced on 8 October

Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the performance in the first nine months of 2020 despite the negative impacts from COVID-19. More patients use our GLP-1 treatments, and our diabetes market leadership continues to expand. Within R&D, an important milestone was reached with the encouraging results from the phase 2b trial in cardiovascular disease with ziltivekimab, the lead candidate from Corvidia Therapeutics that was acquired this year".

On 30 October 2020 at 13.00 CET, corresponding to 8.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com

Company announcement No 63 / 2020



Primary Logo

© GlobeNewswire 2020
All news about NOVO NORDISK A/S
08:56aNOVO NORDISK A/S : - Company announcements, trading in own shares
04:31aNOVO NORDISK A/S : ESG presentation ()
03:41aNOVO NORDISK : Gets a Buy rating from JP Morgan
11/30Weight-Loss Firm Noom Names First CFO
11/23NOVO NORDISK A/S : – Share repurchase programme
11/20India's Gland Pharma jumps 23% in market debut
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
More news
Sales 2020 127 B 20 657 M 20 657 M
Net income 2020 42 174 M 6 838 M 6 838 M
Net cash 2020 8 472 M 1 374 M 1 374 M
P/E ratio 2020 23,0x
Yield 2020 2,16%
Capitalization 965 B 156 B 157 B
EV / Sales 2020 7,51x
EV / Sales 2021 7,05x
Nbr of Employees 44 326
Free-Float 75,1%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 417,00 DKK
Spread / Highest target 30,7%
Spread / Average Target 5,44%
Spread / Lowest Target -30,5%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S8.55%155 951
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389